Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?

• Authors: Veronica Mollica, Alessandro Rizzo, Francesco Massari
• Journal: European urology oncology (Eur Urol Oncol) Vol. 3 Issue 4 Pg. 561-562 (08 2020) ISSN: 2588-9311 [Electronic] Netherlands
• PMID: 32653414 (Publication Type: Letter, Comment)

Chemical References

• Pyrazines
• Triazines
• 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
• Sunitinib

Topics

• Carcinoma, Renal Cell (drug therapy, genetics)
• Goals
• Humans
• Kidney Neoplasms (drug therapy, genetics)
• Pyrazines
• Sunitinib
• Triazines